Neurocrine Biosciences (NBIX) Cash from Operations (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Cash from Operations for 17 consecutive years, with $136.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations rose 33.73% year-over-year to $136.4 million; the trailing twelve-month figure through Jun 2026 stood at $898.1 million (up 58.31% YoY), and the FY2025 full-year result was $782.7 million, up 31.46% from the prior year.
• Cash from Operations declined to $136.4 million in Q2 2026 per NBIX's latest filing, from $145.8 million in the prior quarter.
• Across five years, Cash from Operations topped out at $388.4 million in Q4 2025 and bottomed at -$125.2 million in Q1 2023.
• Historically, Cash from Operations has averaged $132.8 million across 5 years, with a median of $137.2 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations jumped 3304.76% in 2022, then sank 209.14% in 2023.
• Over 5 years, Cash from Operations stood at $143.0 million in 2022, then dropped by 13.64% to $123.5 million in 2023, then jumped by 96.36% to $242.5 million in 2024, then soared by 60.16% to $388.4 million in 2025, then plunged by 64.88% to $136.4 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered $136.4 million, $145.8 million, and $388.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.